Current Cancer Drug Targets
| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | John K. Buolamwini |
| Publication details | |
| History | 2001–present |
| Publisher | |
| Frequency | 9/year |
| 4.771 (2010) | |
| Standard abbreviations | |
| ISO 4 | Curr. Cancer Drug Targets |
| Indexing | |
| CODEN | CCDTB9 |
| ISSN | 1568-0096 (print) 1873-5576 (web) |
| OCLC no. | 48132748 |
| Links | |
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is John K. Buolamwini (University of Tennessee Health Science Center). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").[1]
Abstracting and indexing
Current Cancer Drug Targets is abstracted and indexed in:[2]
According to the Journal Citation Reports, the journal has a 2010 impact factor of 4.771, ranking it 37th of 184 journals in the category "Oncology".[3]
References
- ^ "Journal overview". Current Cancer Drug Targets. Bentham Science Publishers. August 2011. Retrieved 2011-08-04.
- ^ "List of indexing services". Current Cancer Drug Targets. Bentham Science Publishers. August 2011. Retrieved 2011-08-04.
- ^ "Journals Ranked by Impact: Oncology". 2010 Journal Citation Reports (Science ed.). Thomson Reuters. 2011.
{{cite book}}:|access-date=requires|url=(help);|work=ignored (help)CS1 maint: postscript (link)